J Maciel1, D Dias2, D Cavaco2, S Donato2, M C Pereira2, J Simões-Pereira2. 1. Endocrinology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal. joapinheiro.m@gmail.com. 2. Endocrinology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal.
Abstract
PURPOSE: Brain tumors are the most common solid tumor in children. The prevalence of survivors from these cancers has been increasing, presenting endocrine sequelae in more than 40% of the cases. Our aim was to characterize the endocrinopathies diagnosed in this population, exploring the outcomes of growth hormone treatment. METHODS: We have performed a retrospective analysis of the survivors that were followed-up through a close protocol at our endocrine late-effects clinic. RESULTS: 242 survivors, followed during 6.4 (0-23.4) years, were considered. The median age at tumor diagnosis was 6.7 (0-18) years and pilocytic astrocytoma was the most frequent neoplasm (33.5%). The prevalence of endocrinopathies was of 71.5%, with growth hormone deficiency being the most frequent (52.9%). An indirect correlation between the age at the beginning of somatropin and growth velocity in the first year of treatment was observed. Those treated with craniospinal radiotherapy presented a smaller final upper/lower segments ratio comparing with those that only received cranial radiotherapy. However, their final height was not compromised when compared to their family height target. We found pubertal delay in 12%; accelerated/precocious puberty in 13.2%; central and primary hypogonadism in 21.9% and 3.3%, respectively; primary and central hypothyroidism in 23.6% and 14.5%, respectively; thyroid nodules in 7.4%; ACTH deficiency in 10.3% and diabetes insipidus in 12%. CONCLUSION: This study reveals a higher prevalence of endocrinopathies in brain tumors survivors and explores the influence of craniospinal irradiation in the adult body proportions. It reinforces the importance of routine follow-up among survivors.
PURPOSE: Brain tumors are the most common solid tumor in children. The prevalence of survivors from these cancers has been increasing, presenting endocrine sequelae in more than 40% of the cases. Our aim was to characterize the endocrinopathies diagnosed in this population, exploring the outcomes of growth hormone treatment. METHODS: We have performed a retrospective analysis of the survivors that were followed-up through a close protocol at our endocrine late-effects clinic. RESULTS: 242 survivors, followed during 6.4 (0-23.4) years, were considered. The median age at tumor diagnosis was 6.7 (0-18) years and pilocytic astrocytoma was the most frequent neoplasm (33.5%). The prevalence of endocrinopathies was of 71.5%, with growth hormone deficiency being the most frequent (52.9%). An indirect correlation between the age at the beginning of somatropin and growth velocity in the first year of treatment was observed. Those treated with craniospinal radiotherapy presented a smaller final upper/lower segments ratio comparing with those that only received cranial radiotherapy. However, their final height was not compromised when compared to their family height target. We found pubertal delay in 12%; accelerated/precocious puberty in 13.2%; central and primary hypogonadism in 21.9% and 3.3%, respectively; primary and central hypothyroidism in 23.6% and 14.5%, respectively; thyroid nodules in 7.4%; ACTH deficiency in 10.3% and diabetes insipidus in 12%. CONCLUSION: This study reveals a higher prevalence of endocrinopathies in brain tumors survivors and explores the influence of craniospinal irradiation in the adult body proportions. It reinforces the importance of routine follow-up among survivors.
Authors: Adda Grimberg; Sara A DiVall; Constantin Polychronakos; David B Allen; Laurie E Cohen; Jose Bernardo Quintos; Wilma C Rossi; Chris Feudtner; Mohammad Hassan Murad Journal: Horm Res Paediatr Date: 2016-11-25 Impact factor: 2.852
Authors: Sarah A Lawson; Vincent E Horne; Marjorie C Golekoh; Lindsey Hornung; Karen C Burns; Maryam Fouladi; Susan R Rose Journal: Pediatr Blood Cancer Date: 2019-01-28 Impact factor: 3.167
Authors: Aniket Saha; Christina G Salley; Preeti Saigal; Linda Rolnitzky; Judith Goldberg; Suzanne Scott; Randal Olshefski; Juliette Hukin; Stephen A Sands; Jonathan Finlay; Sharon L Gardner Journal: Pediatr Blood Cancer Date: 2014-05-01 Impact factor: 3.167
Authors: Wassim Chemaitilly; Zhenghong Li; Sujuan Huang; Kirsten K Ness; Karen L Clark; Daniel M Green; Nicole Barnes; Gregory T Armstrong; Matthew J Krasin; Deo Kumar Srivastava; Ching-Hon Pui; Thomas E Merchant; Larry E Kun; Amar Gajjar; Melissa M Hudson; Leslie L Robison; Charles A Sklar Journal: J Clin Oncol Date: 2015-01-05 Impact factor: 44.544
Authors: Ralph E Vatner; Andrzej Niemierko; Madhusmita Misra; Elizabeth A Weyman; Claire P Goebel; David H Ebb; Robin M Jones; Mary S Huang; Anita Mahajan; David R Grosshans; Arnold C Paulino; Takara Stanley; Shannon M MacDonald; Nancy J Tarbell; Torunn I Yock Journal: J Clin Oncol Date: 2018-08-17 Impact factor: 44.544
Authors: Sarah C Clement; Antoinette Y N Schouten-van Meeteren; Annemieke M Boot; Hedy L Claahsen-van der Grinten; Bernd Granzen; K Sen Han; Geert O Janssens; Erna M Michiels; A S Paul van Trotsenburg; W Peter Vandertop; Dannis G van Vuurden; Leontien C M Kremer; Hubert N Caron; Hanneke M van Santen Journal: J Clin Oncol Date: 2016-10-31 Impact factor: 44.544